Predicting the Immune Response with NeoScreen™

Are you searching for Neo-Epitopes?

Our unique NeoScreen™ Assay allows you to identify top neo-epitope candidates.

Tell me more!

It’s all about recognition

Immune recognition starts with MHC I and MHC II.

Learn why you can rely on Immunitrack’s competence in manufacturing immune reagents.

Read more
What Immunitrack Does

Our aim is to help our customers predict the immune response. Immunogenicity prediction is a key need in the feld of biologics, particularly for cancer vaccines. We want to help our customers to identify “real” epitopes (those that will cause a T-cell response) from pools of potential neo-epitopes generated by sequencing data.

Conversely (e.g., protein/peptide-based therapeutics), there is often a need to predict if an unwanted immune response can occur.

Watch video

Reagents – Order online!

When you’re investigating the immune response, you need reagents you can rely on.

Immunitrack has an extensive list of the most common MHC/epitope reagents both monomers and tetramers, as well as FcRn. Click on the category of interest to find out more.

Immunitrack proposes also the production of customized MHC I & II reagents as well as MHC binding assays on request. Contact us on to discuss projects.

Latest News
September 10, 2019

Research collaboration – developing new ways of designing vaccines for flaviviruses such as Zika

Read More
August 14, 2019

Immunitrack receives Horizon 2020 funding

Read More
July 5, 2019

Eurostars funding for a novel prediction tool to enhance cancer vaccine performance

Read More
June 17, 2019

Application note: Design of a Neo-Epitope Vaccine

Read More

Moving Biologics Discovery Forward


Identify neo-epitopes faster.

Read more


Identify potent antigens that the patient’s immune system will respond to.

Read more

Precision Medicine

Profile patients for adoptive T-cell therapy.

Read more


Reduce the immunogenicity of therapeutic proteins. Maintain function and develop best-in-class biologics.

Read more

Immunitrack has a stellar reputation in the field of peptide-MHC manufacture. Communication was prompt and clear. Our MHC tetramers arrived within a short timeframe. This allowed us to do faster iterations on our project.

Immunologist Biotech Company, California

Novozymes Biopharma uses the FcRn from Immunitrack to develop the albumin based half-life extension platform Veltis®. We have tested a number of commercially available FcRn’s in our screening assay developed for identification of albumin variants with improved affinity for FcRn receptor and found that the biotinylated FcRn’s from Immunitrack deliver superior performance. These biotinylated FcRn’s enable a robust immobilization to Streptavidin-biosensors (Octet Red96 from Pall ForteBio) and deliver very consistent and robust data.

Birgitte Andersen Science manager, Novozymes